CHAPEL HILL, N.C., April 7, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming CHI conferences. Dr. Fernandes will present at the Second Annual Anti-Inflammatories: Small Molecule Approaches Conference at 5 p.m. PDT, April 12, at the Hilton San Diego Resort in San Diego. Her presentation is entitled "Macrolides as a New Class of Orally Active Anti-Inflammatory Agents." Her presentation will include a discussion on the mechanism of macrolide action as anti-inflammatory agents and the use of macrolides in COPD patients. Data on the potent anti-inflammatory activities of solithromycin (CEM-101), Cempra's fluoroketolide candidate in Phase 2 clinical development for community-acquired bacterial pneumonia (CABP), as well as novel macrolides without antibacterial activity will be presented.
Dr. Fernandes will present at the Fifth Annual Resistance is Futile: The Challenge of Antibacterial Drug Development Conference at 10:45 a.m. PDT, April 13, at the Hilton San Diego Resort in San Diego. Her presentation is entitled "Solithromycin: A Well-Tolerated Fluoroketolide with Broad Spectrum, Potent Activity" and will provide an overview of the potential clinical value of an oral and intravenous macrolide in treating drug-resistant pathogens.
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.
Robert E. Flamm, Ph.D.
Russo Partners, LLC
Tony Russo, Ph.D.
Russo Partners, LLC
SOURCE Cempra Pharmaceuticals Inc.